logo
logo
HLN stock ticker logo

Haleon plc

NYSE•HLN
CEO: Mr. Brian James McNamara
セクター: Healthcare
業種: Drug Manufacturers - Specialty & Generic
上場日: 2022-07-25
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
連絡先情報
The Heights, Building 5, First Floor, Weybridge, KT13 0NY, United Kingdom
44-1932-822000
www.haleon.com
時価総額
$46.01B
PER (TTM)
22.7
57.6
配当利回り
1.5%
52週高値
$11.42
52週安値
$8.71
52週レンジ
60%
順位34Top 27.8%
4.7
F-Score
改良版 Piotroski 分析
6年ファンダメンタル
堅調 • 4.7 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2020-2025

財務ダッシュボード

Q4 2025 データ

売上高

$7.39B+0.00%
直近4四半期の推移

EPS

$0.25+0.00%
直近4四半期の推移

フリーCF

$1.68B+0.00%
直近4四半期の推移

2024 Annual 決算ハイライト

主なハイライト

Organic Revenue Growth Strong Organic revenue grew 5.0% for 2024; reported revenue declined (0.6)% to £11.2bn due to FX headwinds.
Profitability and Margin Expansion Operating profit reached £2.2bn, up 10.5% reported; adjusted operating margin grew 100bps organically to 22.3%.
Deleveraging and Shareholder Returns Returned over £1bn to shareholders via buybacks and dividends; Net debt/adjusted EBITDA reduced to 2.8x.
Health Inclusivity Target Achieved Empowered over 50m people against health inclusivity goal, achieving the 2025 target one year ahead of plan.

リスク要因

FX Headwinds Impact Reported Revenue Adverse foreign exchange movements caused £421m negative impact on reported revenue decline of (0.6)%.
Increased Cyber Security Threat Profile Cyber security risk increased due to rising sophistication of threats, third-party exposure, and new risks from AI adoption.
Geopolitical Instability Risk Rises Geopolitical instability risk increased reflecting ongoing conflicts and rising protectionism impacting global operations and talent movement.
Supply Chain Resilience Tested Global sourcing network faces disruption from geopolitical instability, extreme weather, and commodity volatility impacting service levels.

見通し

Medium-Term Revenue Guidance Medium-term guidance targets annual organic revenue growth between 4-6% supported by portfolio strength.
2025 Profit Growth Ahead Expecting 2025 organic revenue growth of 4-6%, with organic operating profit growth anticipated to be ahead of revenue.
Continued Capital Allocation Discipline Board approved £500m capital allocation for share buybacks in 2025, balancing investment and shareholder returns.
Evolving Strategy and Culture Priorities for 2025 include continued transformation into agile business and evolving culture to capitalize on opportunities.

同業比較

売上高 (TTM)

CAH stock ticker logoCAH
$244.49B
+10.1%
HUM stock ticker logoHUM
$129.66B
+10.1%
TAK stock ticker logoTAK
$30.01B
-2.0%

粗利益率 (最新四半期)

INSM stock ticker logoINSM
82.5%
-18.6pp
EW stock ticker logoEW
78.3%
-2.7pp
ZTS stock ticker logoZTS
68.9%
+2.4pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
BDX$61.57B27.66.9%35.6%
TAK$56.11B78.81.6%31.5%
ZTS$53.87B20.058.2%61.4%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
1.3%
緩やかな成長
4四半期純利益CAGR
7.7%
収益性の着実な向上
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい

深度リサーチ

次回決算:2026年4月29日
|
EPS:-
|
売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書
直近12ヶ月
データなし